PF-07224826

N/A

Report date: 2023/11/09 20:00:57
NME

Base Information

Drug NamePF-07224826
Drug Alias NamePF-07224826
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 2 inhibitorsCyclin-dependent kinase 4 inhibitorsCyclin-dependent kinase 6 inhibitors
TargetsCyclin-dependent kinase 2Cyclin-dependent kinase 4Cyclin-dependent kinase 6
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[6] 

Other Information

ATC CodeN/A
Related LinksN/A